This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

FeNO and Cytokines in Respiratory Syncytial Virus (RSV) and Non RSV Bronchiolitis in Relation to Future Asthma

This study is currently recruiting participants.
See Contacts and Locations
Verified June 2014 by Tel-Aviv Sourasky Medical Center
Sponsor:
Information provided by (Responsible Party):
Tel-Aviv Sourasky Medical Center
ClinicalTrials.gov Identifier:
NCT02093715
First received: March 19, 2014
Last updated: August 31, 2014
Last verified: June 2014
  Purpose
The purpose of this study is to determine Fractional exhaled Nitric-Oxide (FeNO)levels and blood cytokines during acute bronchiolitis, and to seek for correlation between these markers and future development of asthma.

Condition
Acute Bronchiolitis

Study Type: Observational [Patient Registry]
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 7 Years
Official Title: FeNO and Cytokines in RSV and Non RSV Bronchiolitis in Relation to Future Asthma

Further study details as provided by Tel-Aviv Sourasky Medical Center:

Primary Outcome Measures:
  • Physician diagnosed asthma [ Time Frame: At the age of 4 years ]
    Modification of The International Study of Asthma and Allergies in Childhood (ISAAC) questionnaires


Secondary Outcome Measures:
  • Fractional exhaled Nitric Oxide (FENO) level [ Time Frame: During acute bronchiolitis, after 2 and 6 months ]
    FeNO level measured by a rapid-response chemiluminescence analyzer (Eco Physics CLD88 NO analyzer, EcoMedics AG,Switzerland).


Other Outcome Measures:
  • Wheezing episode [ Time Frame: From recruitment time till the age 4. ]
  • PCR for respiratory viruses [ Time Frame: At recruitment ]
    Polymerase chain reaction (PCR) analysis of nasal secretion for: RSV, Influenza A, Influenza B, Pandemic H1N1, Adenovirus, human metapneumovirus (hMPV), Parainfluenza 1-3, Enterovirus, Bocavirus, Rhinovirus, Corona virus-229E, Corona-OC43, Corona-HKU1 and Corona-NL63.


Biospecimen Retention:   Samples Without DNA
blood

Estimated Enrollment: 400
Study Start Date: July 2007
Estimated Primary Completion Date: August 2020 (Final data collection date for primary outcome measure)
Groups/Cohorts
RSV
Infant with acute bronchiolitis due to RSV
Co- Infection
Infant with acute bronchiolitis due to RSV and other respiratory virus
Other
Infant with acute bronchiolitis due to non-RSV respiratory virus
Unknown
Infant with acute bronchiolitis with negative PCR results for respiratory viruses
Control
Healthy infants

  Eligibility

Ages Eligible for Study:   up to 2 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Children ages 2 weeks to 2 years who will arrive to Dana Children's hospital, Tel-Aviv Medical Center due to first episode of shortness of breath and working diagnosis of bronchiolitis.
Criteria

Inclusion Criteria:

  • First episode of shortness of breath
  • Children in ages 2 weeks to 2 years

Exclusion Criteria:

  • Any chronic disease
  • Congenital anomalies
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02093715

Contacts
Contact: Yakov Sivan, Professor sivan@tlvmc.gov.il

Locations
Israel
Sourasky Medical Center Recruiting
Tel-Aviv, Israel
Sponsors and Collaborators
Tel-Aviv Sourasky Medical Center
  More Information

Responsible Party: Tel-Aviv Sourasky Medical Center
ClinicalTrials.gov Identifier: NCT02093715     History of Changes
Other Study ID Numbers: TASMC-13-YS-07-075-CTIL
Study First Received: March 19, 2014
Last Updated: August 31, 2014

Keywords provided by Tel-Aviv Sourasky Medical Center:
Bronchiolitis
FeNO
Asthma
wheezing, RSV

Additional relevant MeSH terms:
Bronchiolitis
Bronchitis
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Tract Infections

ClinicalTrials.gov processed this record on June 23, 2017